Literature DB >> 1524075

Significant developmental elevation in serum parathyroid hormone levels in a large kindred with familial benign (hypocalciuric) hypercalcemia.

C T McMurtry1, F W Schranck, D A Walkenhorst, W A Murphy, D B Kocher, S L Teitelbaum, R C Rupich, M P Whyte.   

Abstract

PURPOSE: A large kindred with familial benign hypercalcemia (FBH) is described because of the new observation of developmental increases in serum immunoreactive parathyroid hormone (iPTH) levels in affected individuals that lead to significantly elevated values in adults. PATIENTS AND METHODS: After identification of the proposita, 46 kindred members spanning 5 generations, ages 1.5 to 91 years, were surveyed biochemically and/or studied by chart review. Two hypercalcemic adults underwent biopsy of the iliac crest following tetracycline labeling for histomorphometric study.
RESULTS: Of the 46 individuals studied, 19 were found to be affected. Serum iPTH levels, determined in three separate immunoassays, became supranormal by about age 30 years in the group of 15 hypercalcemic subjects examined biochemically and appeared to increase further thereafter. Serum alkaline phosphatase activity and creatinine levels were normal in these individuals, but inorganic phosphate levels were lower than in unaffected kindred members. Three of five affected adults older than age 40 years who were studied radiographically had changes suggestive of osteomalacia. Biopsy of the iliac crest of one of the subjects, a 51-year-old woman, confirmed the presence of defective skeletal mineralization.
CONCLUSIONS: In this kindred, FBH in adults can be especially difficult to distinguish from primary hyperparathyroidism because serum iPTH levels may be elevated. Furthermore, the disorder may not be totally benign. Osteomalacia, perhaps due to mild hypophosphatemia, can develop during adulthood. Review of data from other kindreds for evidence of developmental elevations in serum iPTH levels with careful search for skeletal disease in late adult life will help to clarify if we have observed an unusual variant of FBH.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524075     DOI: 10.1016/0002-9343(92)90229-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

Authors:  Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 2.  Familial hypocalciuric hypercalcemia and related disorders.

Authors:  Janet Y Lee; Dolores M Shoback
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2018-05-26       Impact factor: 4.690

3.  Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism.

Authors:  S H Pearce; D Trump; C Wooding; G M Besser; S L Chew; D B Grant; D A Heath; I A Hughes; C R Paterson; M P Whyte
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 4.  Familial benign hypercalcemia--from clinical description to molecular genetics.

Authors:  H Heath
Journal:  West J Med       Date:  1994-06

5.  Comparison of human chromosome 19q13 and syntenic region on mouse chromosome 7 reveals absence, in man, of 11.6 Mb containing four mouse calcium-sensing receptor-related sequences: relevance to familial benign hypocalciuric hypercalcaemia type 3.

Authors:  Fadil M Hannan; M Andrew Nesbit; Jeremy J O Turner; Joanna M Stacey; Luisella Cianferotti; Paul T Christie; Arthur D Conigrave; Michael P Whyte; Rajesh V Thakker
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

6.  Linkage studies in a kindred from Oklahoma, with familial benign (hypocalciuric) hypercalcaemia (FBH) and developmental elevations in serum parathyroid hormone levels, indicate a third locus for FBH.

Authors:  D Trump; M P Whyte; C Wooding; J T Pang; S H Pearce; D B Kocher; R V Thakker
Journal:  Hum Genet       Date:  1995-08       Impact factor: 4.132

7.  Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13.

Authors:  S E Lloyd; A A Pannett; P H Dixon; M P Whyte; R V Thakker
Journal:  Am J Hum Genet       Date:  1999-01       Impact factor: 11.025

Review 8.  Therapeutic Opportunities of Targeting Allosteric Binding Sites on the Calcium-Sensing Receptor.

Authors:  Jiayin Diao; Aaron DeBono; Tracy M Josephs; Jane E Bourke; Ben Capuano; Karen J Gregory; Katie Leach
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-08

9.  Ap2s1 mutation causes hypercalcaemia in mice and impairs interaction between calcium-sensing receptor and adaptor protein-2.

Authors:  Fadil M Hannan; Mark Stevenson; Asha L Bayliss; Victoria J Stokes; Michelle Stewart; Kreepa G Kooblall; Caroline M Gorvin; Gemma Codner; Lydia Teboul; Sara Wells; Rajesh V Thakker
Journal:  Hum Mol Genet       Date:  2021-05-29       Impact factor: 6.150

Review 10.  The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases.

Authors:  Fadil M Hannan; Enikö Kallay; Wenhan Chang; Maria Luisa Brandi; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2018-12       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.